Evidence map›Paper›PMID 40047860›Full record

SynthesisNaunyn-Schmiedeberg's archives of pharmacology2025

Efficacy and safety of edaravone dexborneol in acute ischemic stroke: systematic review and meta-analysis of randomized controlled trials.

Muataz Kashbour, Abdelrahman Shata, Mohamed Wagdy, Asmaa Zakria Alnajjar, Mohamed A Aldemerdash, Husam Tarakhan, Moaz Elsayed Abouelmagd

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muataz KashbourDiagnostic Radiology Department, National Cancer Institute, Misrata, Libya. Moutaz.om17@gmail.com.ORCID 0000-0002-5624-0017
Abdelrahman ShataMedical Research Group of Egypt, Negida Academy, Arlington, MA, USA.ORCID 0009-0008-0704-6585
Mohamed WagdyMedical Research Group of Egypt, Negida Academy, Arlington, MA, USA.ORCID 0009-0009-0891-3561
Asmaa Zakria AlnajjarMedical Research Group of Egypt, Negida Academy, Arlington, MA, USA.ORCID 0000-0002-1254-4289
Mohamed A AldemerdashMedical Research Group of Egypt, Negida Academy, Arlington, MA, USA.
Husam TarakhanMedical Research Group of Egypt, Negida Academy, Arlington, MA, USA.ORCID 0000-0001-7130-7905
Moaz Elsayed AbouelmagdMedical Research Group of Egypt, Negida Academy, Arlington, MA, USA.ORCID 0000-0002-0511-2429

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionStroke is a leading cause of global morbidity and mortality, with acute ischemic stroke (AIS) accounting for most cases. Despite advancements in reperfusion therapies, many patients do not achieve sufficient reperfusion, necessitating effective neuroprotective interventions. This meta-analysis evaluates the efficacy and safety of Edaravone Dexborneol (ED) compared to standard therapies in AIS treatment.

methodsA systematic review and meta-analysis were conducted according to PRISMA guidelines, including randomized controlled trials (RCTs) investigating ED in AIS. Primary outcomes included Modified Rankin Scale (mRS ≤ 1) at 90 days and changes in National Institutes of Health Stroke Scale (NIHSS) scores. Pooled effect sizes were calculated using random-effects models.

resultsFive RCTs with 2,535 patients (1,263 ED, 1,272 control) were included. ED significantly improved the odds of achieving mRS ≤ 1 at 90 days (OR = 1.47, 95% CI [1.25-1.74], p < 0.00001). While NIHSS score changes at 14 days were not significant (p = 0.35), ED showed significant improvement at 30 days (MD = -1.77, 95% CI [-2.82 to -0.72], p = 0.0009). ED also significantly reduced the risk of hemorrhagic transformation (OR = 0.47, 95% CI [0.24-0.92], p = 0.03) and mortality rates were lower in the ED group but not statistically significant (OR = 0.66, 95% CI [0.41-1.06], p = 0.08, I

conclusionED demonstrates significant neuroprotective benefits in AIS by improving functional outcomes and reducing the risk of hemorrhagic transformation. However, further studies with larger sample sizes must confirm these findings and optimize treatment protocols.

Indexed as

EdaravoneIschemic StrokeNeuroprotective AgentsHumansRandomized Controlled Trials as TopicTreatment OutcomeEdaravoneNeuroprotective AgentsAcute ischemic strokeEdaravone DexborneolIschemic strokeMeta-analysisNeuroprotective agents

Identifiers

PMID40047860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.